Spoilt for choice: different immunosuppressive potential of anaplastic lymphoma kinase inhibitors for non small cell lung cancer

Spoilt for choice: different immunosuppressive potential of anaplastic lymphoma kinase inhibitors for non small cell lung cancer

IntroductionSeveral anaplastic lymphoma kinase (ALK)-inhibitors (ALKi) have been approved for the treatment of ALK-translocated advanced or metastatic Non Small Cell Lung Cancer (NSCLC), amongst crizotinib and alectinib. This forces physicians to choose the most suitable compound for each individual...

Full description

Bibliographic Details
Main Authors: Annkristin Heine, Stefanie Andrea Erika Held, Solveig Nora Daecke, Chrystel Flores, Peter Brossart
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Immunology
Subjects:
alectinib
crizotinib
dendritic cells
immunosuppression
anaplastic lymphoma kinase (ALK) inhibitor
non-small cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1257017/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1257017/full

Similar Items